Sagimet Biosciences Inc (NASDAQ:SGMT) has a beta value of 3.36 and has seen 1.04 million shares traded in the last trading session. The company, currently valued at $290.18M, closed the last trade at $9.46 per share which meant it lost -$0.01 on the day or -0.11% during that session. The SGMT stock price is -10.25% off its 52-week high price of $10.43 and 81.71% above the 52-week low of $1.73. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.88 million shares traded. The 3-month trading volume is 1.54 million shares.
The consensus among analysts is that Sagimet Biosciences Inc (SGMT) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight.
Sagimet Biosciences Inc (NASDAQ:SGMT) trade information
Sporting -0.11% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the SGMT stock price touched $9.46 or saw a rise of 5.21%. Year-to-date, Sagimet Biosciences Inc shares have moved 196.55%, while the 5-day performance has seen it change 8.99%. Over the past 30 days, the shares of Sagimet Biosciences Inc (NASDAQ:SGMT) have changed 52.83%. Short interest in the company has seen 3.81 million shares shorted with days to cover at 1.54.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could drop -57.67% from current levels. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the current price level is 36.58% off the targeted high while a plunge would see the stock lose 36.58% from current levels.
Sagimet Biosciences Inc (SGMT) estimates and forecasts
The company’s shares have gained 76.16% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -16.85% over the past 5 years. Earnings growth for 2025 is a modest -54.40% while over the next 5 years, the company’s earnings are expected to decrease by -25.74%.
SGMT Dividends
Sagimet Biosciences Inc is expected to release its next earnings report on 2025-May-08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Sagimet Biosciences Inc (NASDAQ:SGMT)’s Major holders
Insiders own 13.31% of the company shares, while shares held by institutions stand at 44.74% with a share float percentage of 51.62%. Investors are also buoyed by the number of investors in a company, with Sagimet Biosciences Inc having a total of 86.0 institutions that hold shares in the company. The top two institutional holders are POINT72 ASSET MANAGEMENT, L.P. with over 2.37 million shares worth more than $8.09 million. As of 2024-06-30, POINT72 ASSET MANAGEMENT, L.P. held 7.414% of shares outstanding.
The other major institutional holder is NEA MANAGEMENT COMPANY, LLC, with the holding of over 2.0 million shares as of 2024-06-30. The firm’s total holdings are worth over $6.84 million and represent 6.2677% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and BlackRock Health Sciences Term Trust . As of Mar 31, 2025 , the former fund manager holds about 2.49% shares in the company for having 763.99 shares of worth $7.23 million while later fund manager owns 408.12 shares of worth $3.86 million as of Mar 31, 2025 , which makes it owner of about 1.33% of company’s outstanding stock.
